Venus Remedies inaugurates 1,32,000 sq. ft State-of-the-Art Global Fulfillment Center to Elevate Supply Across 100+ Countries

• Venus Global Fulfillment Center (VGFC) operates in full compliance with global pharmaceutical standards and can process up to 10,000 orders per day across B2B and B2C channels
• Facility integrates human expertise and advanced operational processes to strengthen global supply chain, supporting timely access to critical medicines and improved patient outcomes

CHANDIGARH: Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), among the 10 leading fixed-dosage injectable manufacturers in the world, has inaugurated its state-of-the-art Venus Global Fulfillment Center (VGFC). Spanning 132,000 square feet with a built-up area of 66,000 square feet, the facility is designed to significantly enhance the company’s global logistics and supply chain capabilities.

Built to meet international standards including WHO GDP, EU GMP, PAHO, CDSCO, GDP AEO, and ISO certifications, the VGFC ensures product integrity, quality compliance, and timely access to medicines across regulated and semi-regulated markets.

The center can process up to 10,000 orders per day across B2B and B2C channels, with current utilization at approximately 30,000 orders per month. Its infrastructure includes temperature-controlled storage, RFID and barcode-based tracking, and automated sorting and retrieval systems. With capacity for more than 5,000 pallets and storage for over 50 million product units, VGFC is equipped to support dynamic global demand while maintaining precision and reliability.

“The VGFC represents a strategic advancement in our global supply framework,” said Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and CEO, Venus Medicine Research Centre. “It enhances our responsiveness to urgent healthcare needs and supports uninterrupted patient access across over 100 countries.”

Ms. Aditi K. Chaudhary, President, International Business, Venus Remedies Limited, added, “Every process within VGFC has been designed for speed, transparency, and consistency. From inventory management to final dispatch, the focus is on ensuring that every shipment meets the highest benchmarks of quality and reliability.”

Commenting on the operational significance, Mr. Peeyush Jain, Deputy Managing Director and Head of Supply Chain, Venus Remedies Limited, said, “The VGFC is built to bring greater resilience and agility to our global supply chain. By combining automation with skilled human oversight, we can process large order volumes with high precision while maintaining full regulatory compliance. This facility strengthens our ability to anticipate and respond to market needs efficiently, ensuring that critical medicines reach patients on time, every time.”

The facility also aligns with Venus Remedies’ sustainability objectives, integrating energy-efficient HVAC systems, rainwater harvesting, waste management through authorized partners, and eco-conscious logistics practices.

With VGFC, Venus Remedies strengthens its ability to serve critical care, oncology, and antimicrobial markets worldwide, supporting the company’s vision to deliver safe, high-quality medicines with operational excellence and global reliability.

About Venus Remedies Ltd (venusremedies.com)

Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 90+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. The company holds the GMP approvals from European- GMP (INFARMED), PIC/S (Malaysia & Ukraine), SAHPRA, UNICEF, TGA, INVIMA & WHO-GMP, alongside key ISO certifications for quality, environmental, and occupational health and safety management.

Central to its mission, Venus Remedies is a frontrunner in combating antimicrobial resistance (AMR) through its dedicated research division, Venus Medicine Research Centre (VMRC). The company is pivotal in developing advanced antibiotics and β-lactam/β-lactamase inhibitor combinations aimed at tackling multidrug-resistant pathogens. Its notable initiatives like GASAR provide essential data on antibiotic resistance, while the PLEA Trust fosters antibiotic stewardship. As an influential member of the AMR Industry Alliance, India AMR Innovation Hub, and Vivli AMR Registry, Venus Remedies shapes global AMR research and policy. Through strategic collaborations with academic and health organizations worldwide, the company enhances AMR surveillance and supports innovative drug development, affirming its leadership in global healthcare.